DNA
Ginkgo Bioworks Holdings
NYSE: DNA · HEALTHCARE · BIOTECHNOLOGY
$10.23
-0.20% today
Updated 2026-11-12
Market cap
$754.88M
P/E ratio
—
P/S ratio
5.70x
EPS (TTM)
$-5.06
Dividend yield
—
52W range
$5 – $18
Volume
2.7M
Ginkgo Bioworks Holdings (DNA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$10.23
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$7.32
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.3B | $0.5B | $0.3B | $0.2B | $0.2B | $0.2B | $0.2B | $0.3B | $0.3B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 17.29% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -219.60%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.